WO2009033183A3 - Compounds and methods for treatment of hcv and conditions associated with cd81 binding - Google Patents

Compounds and methods for treatment of hcv and conditions associated with cd81 binding Download PDF

Info

Publication number
WO2009033183A3
WO2009033183A3 PCT/US2008/075644 US2008075644W WO2009033183A3 WO 2009033183 A3 WO2009033183 A3 WO 2009033183A3 US 2008075644 W US2008075644 W US 2008075644W WO 2009033183 A3 WO2009033183 A3 WO 2009033183A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treatment
hcv
binding
compounds
Prior art date
Application number
PCT/US2008/075644
Other languages
French (fr)
Other versions
WO2009033183A2 (en
Inventor
Chen Liu
David A. Ostrov
Original Assignee
University Of Florida Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation filed Critical University Of Florida Research Foundation
Publication of WO2009033183A2 publication Critical patent/WO2009033183A2/en
Publication of WO2009033183A3 publication Critical patent/WO2009033183A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

The invention features compositions and methods that are useful for treating or preventing HCV infection and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of HCV infection and associated conditions.
PCT/US2008/075644 2007-09-08 2008-09-08 Compounds and methods for treatment of hcv and conditions associated with cd81 binding WO2009033183A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97095107P 2007-09-08 2007-09-08
US60/970,951 2007-09-08

Publications (2)

Publication Number Publication Date
WO2009033183A2 WO2009033183A2 (en) 2009-03-12
WO2009033183A3 true WO2009033183A3 (en) 2009-12-30

Family

ID=40429751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075644 WO2009033183A2 (en) 2007-09-08 2008-09-08 Compounds and methods for treatment of hcv and conditions associated with cd81 binding

Country Status (1)

Country Link
WO (1) WO2009033183A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DK2583677T1 (en) 2011-10-21 2015-01-19 Abbvie Inc Methods for treatment of HCV comprising at least two direct-acting antiviral agents ribavirin, interferon but not
CN102942528B (en) * 2012-10-31 2014-09-10 华南理工大学 2-sulfo hydantoin derivative, its preparation method and application
CN103087108B (en) * 2012-11-28 2015-09-30 辽宁师范大学 2-[nitrogen-(triphenylmethyl) imino-] pyridine-2-chromium nitrate salt compound and preparation method thereof
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176662A1 (en) * 2000-07-03 2003-09-18 Martino Bolognesi Structure-based hepatitis c virus drug design
US20050003348A1 (en) * 2003-05-09 2005-01-06 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US20060246421A1 (en) * 2005-05-01 2006-11-02 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication
US20070099844A1 (en) * 2003-03-27 2007-05-03 Prendergast George C Novel methods for the treatment of cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176662A1 (en) * 2000-07-03 2003-09-18 Martino Bolognesi Structure-based hepatitis c virus drug design
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20070099844A1 (en) * 2003-03-27 2007-05-03 Prendergast George C Novel methods for the treatment of cancer
US20050003348A1 (en) * 2003-05-09 2005-01-06 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
US20060246421A1 (en) * 2005-05-01 2006-11-02 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRUMMER ET AL.: "Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81.", JOURNAL OF VIROLOGY, vol. 76, no. 21, November 2002 (2002-11-01), pages 11143 - 11147 *
GLATER ET AL.: "The search for a chlorine-resistant reverse osmosis membrane.", DESALINATION, vol. 95, 1994, pages 325 - 345 *
HIGGINBOTTOM ET AL.: "Identification of Amino Acid Residues in CD81 Critical for Interaction with Hepatitis C Virus Envelope Glycoprotein E2.", JOURNAL OF VIROLOGY, April 2000 (2000-04-01), pages 3642 - 3649 *
VANCOMPERNOLLE ET AL.: "Small molecule inhibition of hepatitis C virus E2 binding to CD81.", VIROLOGY, vol. 314, 2003, pages 371 - 380 *

Also Published As

Publication number Publication date
WO2009033183A2 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2008143633A3 (en) Compounds and methods for treatment of alpha-1 antitrypsin deficiency
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2009129246A3 (en) Compositions and methods for preparing and using same
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
WO2006024018A3 (en) Compositions for treating nociceptive pain
MX2009006536A (en) Organic compounds and their uses.
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006104945A3 (en) Hepatitis c therapies
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2009052431A3 (en) Cd19 binding agents and uses thereof
WO2010062396A3 (en) Virus like particle compositions and methods of use
MX2009009761A (en) Compositions and kits for treating influenza.
ZA200708575B (en) Methods and compositions for treating or preventing cancer
WO2008013589A3 (en) Treatment of ras-expressing tumors
EP2331093A4 (en) Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2008027600A3 (en) Imatinib compositions
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08829468

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08829468

Country of ref document: EP

Kind code of ref document: A2